Table 4.
AS&AQ groups: crude and PCR-adjusted Day 28 efficacy results presented by site and country
| Efficacy by Day 28 by country and site * | Number of patients enrolled receiving ASAQ | Crude (not adjusted for reinfection) | PCR-adjusted | ||||
| Efficacy | Lower 95% confidence interval | Upper 95% confidence interval | Efficacy | Lower 95% confidence interval | Upper 95% confidence interval | ||
| Angola (all) | 166 | 92.0% | 83.0% | 96.3% | 98.6% | 90.5% | 99.8% |
| Angola-Caala | 69 | 91.0% | 81.1% | 95.9% | 98.4% | 89.3% | 99.8% |
| Angola-Kuito | 97 | 92.9% | 84.9% | 96.8% | 98.8% | 91.7% | 99.8% |
| Burkina Faso (all) | 923 | 96.7% | 91.4% | 97.5% | NA | NA | NA |
| Burkina Faso-Bobo-Dilaossou | 33 | 100% | 91.3% | 100.0% | NA | NA | NA |
| Burkina Faso-Pouytenga | 890 | 93.5% | 91.5% | 95.0% | 97.3% | 95.9% | 98.2% |
| Cameroun-Mendong | 110 | 98.1% | 92.5% | 99.5% | 100.0% | 100.0% | 100.0% |
| Congo-Kindamba# | 101 | 67.5% | 57.0% | 75.9% | 84.2% | 74.8% | 90.4% |
| Gabon-Lambarene | 110 | 87.5% | 79.1% | 92.7% | 94.5% | 87.3% | 97.7% |
| Guinea-Dabola | 110 | 94.4% | 87.9% | 97.4% | 99.1% | 93.6% | 99.9% |
| Kenya-Migori# | 200 | 76.5% | 69.1% | 82.4% | 89.5% | 83.4% | 93.5% |
| Madagascar-Tsiroanomandidy | 119 | 96.6% | 91.2% | 98.7% | 99.2% | 94.1% | 99.9% |
| Mali (all) | 387 | 74.5% | 67.4% | 80.4% | 98.3% | 94.6% | 99.5% |
| Mali-Bancoumana | 135 | 68.5% | 59.7% | 75.7% | 97.5% | 92.3% | 99.2% |
| Mali-Bougoula | 252 | 80.6% | 75.1% | 85.0% | 99.2% | 96.8% | 99.8% |
| DRC (all) | 136 | 74.5% | 62.5% | 82.0% | 88.3% | 76.6% | 93.1% |
| DRC-Boende# | 90 | 57.7% | 46.5% | 67.4% | 78.7% | 67.6% | 86.4% |
| DRC-Kabalo | 46 | 91.3% | 78.5% | 96.6% | 97.8% | 85.6% | 99.7% |
| Rwanda (all) | 410 | 82.4% | 75.1% | 87.5% | 91.6% | 85.6% | 95.0% |
| Rwanda-Kicukiro | 122 | 91.6% | 85.0% | 95.4% | 95.8% | 90.2% | 98.2% |
| Rwanda-Mashesha | 150 | 86.7% | 80.1% | 91.2% | 95.3% | 90.3% | 97.7% |
| Rwanda-Rukara# | 138 | 68.8% | 60.2% | 75.9% | 83.8% | 76.1% | 89.1% |
| Sénégal (all) | 1390 | 96.1% | 91.4% | 98.5% | NA | NA | NA |
| Senegal-Keur Socé | 264 | 94.2% | 90.9% | 96.7% | 99.2% | 96.8% | 99.8% |
| Senegal-Djembeye | 110 | 95.3% | 91.3% | 99.3% | NA | NA | NA |
| Senegal-Kabrousse | 27 | 100% | 89.1% | 100.0% | NA | NA | NA |
| Senegal-Mlomp | 883 | 95.8% | 94.4% | 97.2% | NA | NA | NA |
| Senegal-Oussouye | 106 | 95.3% | 91.3% | 99.3% | NA | NA | NA |
| Sierra-Leone-kailahun# | 126 | 40.5% | 31.5% | 49.4% | 87.5% | 78.5% | 92.9% |
| Sudan (all) | 214 | 76.1% | 66.8% | 83.1% | 88.4% | 79.8% | 93.4% |
| South Sudan-Nuba# | 80 | 63.8% | 52.2% | 73.2% | 84.9% | 74.4% | 91.4% |
| Sudan-Malakal | 134 | 88.5% | 81.3% | 93.0% | 91.8% | 85.3% | 95.5% |
| Uganda (all) | 1283 | 53.3% | 46.5% | 59.6% | 91.1% | 85.1% | 94.7% |
| Uganda-Amudat# | 106 | 30.3% | 21.3% | 39.9% | 89.9% | 79.2% | 95.2% |
| Uganda-Apac# | 174 | 46.5% | 38.9% | 53.8% | 87.2% | 80.6% | 91.7% |
| Uganda-Arua# | 174 | 49.3% | 41.7% | 56.6% | 88.8% | 82.5% | 92.9% |
| Uganda-Jinja | 189 | 79.5% | 72.9% | 84.6% | 94.3% | 89.6% | 96.9% |
| Uganda-Kampala | 242 | 83.8% | 78.4% | 87.9% | 95.7% | 92.1% | 97.7% |
| Uganda-Tororo | 398 | 30.2% | 25.7% | 34.8% | 91.1% | 86.8% | 94.0% |
| Zanzibar (all) | 202 | 75.6% | 64.9% | 83.3% | 91.8% | 83.1% | 96.2% |
| Zanzibar-Kivunge | 148 | 73.5% | 65.5% | 79.9% | 95.0% | 89.7% | 97.6% |
| Zanzibar-Micheweni# | 54 | 77.8% | 64.2% | 86.7% | 88.7% | 76.5% | 94.7% |
*Mean efficacies are given for countries with multiple sites
# Efficacy PCR adjusted <90%
NA: not applicable, no PCR genotyping data for all sites from that country